From The People's Pharmacy 1st Oct 2021 and good news for immunocompromised patients like us.
" Today, the Merck company, together with Ridgeback Biotherapeutics, the company that originally developed molnupiravir, announced the results from a clinical trial. Independent experts monitoring the trial recommended it be stopped early because the results were so clear.
Molnupiravir cuts the risk for serious COVID-19 infection and hospitalization by about 50%. In this clinical trial, 775 unvaccinated people with confirmed cases of COVID-19 took either molnupiravir or a look-alike placebo pill. All of these volunteers had pre-existing conditions putting them at high risk for severe disease. In other words, they were obese or elderly. They started taking the medicine within five days of initial symptoms.
None of the people taking the drug died, but eight individuals in the placebo arm did. About 7 percent of those getting molnupiravir were hospitalized. Twice that many taking placebo pills were hospitalized or died. The safety monitors thought that made it unethical to continue the trial with people on placebo.
Laboratory research indicates that the drug is equally active against delta, gamma and other variants of SARS-CoV-2. Some scientists speculate it might even help protect people from other coronaviruses.
Merck and Ridgeback will be submitting the data and an application for emergency use application to the FDA. That is the same process that has been used for vaccines and the monoclonal antibodies. That puts it on an ultra-fast track for patient access.
The drug company has already started making pills. That’s a pretty clear indication that 1) Merck believes the medication is effective and 2) the FDA will grant EUA. The US government has already committed over $1 billion for the first pills that come off the production line.
To be maximally effective, most antiviral medications need to be taken at the very first sign of infection. That’s how antiviral drugs like Tamiflu (oseltamivir) work against influenza. If someone is exposed to the coronavirus, molnupiravir might be used preventively but research has not yet demonstrated such a tactic.
We have not yet seen the data about side effects with molnupiravir, so we don’t know how well people will tolerate this new medicine. Nonetheless, an oral drug against COVID-19 that is taken at home could be a real step forward in managing this pandemic."
peoplespharmacy.com/article...
Jackie